Sleep Disorder Connect
  • Saved

2yr
Deficiency of Orexin Signaling During Sleep Is Involved in Abnormal REM Sleep Architecture in Narcolepsy

Deficiency of Orexin Signaling During Sleep Is Involved in Abnormal REM Sleep Architecture in Narcolepsy

Source : https://pubmed.ncbi.nlm.nih.gov/37796986/

Narcolepsy is a sleep disorder caused by deficiency of orexin signaling. However, the neural mechanisms by which deficient orexin signaling causes the abnormal rapid eye movement (REM) sleep characteristics of...

Inhibition of orexin neurons during REM sleep increased subsequent REM sleep in "orexin intact" mice and subsequent cataplexy in mice lacking orexin peptides, indicating that the activity of a subpopulation of orexin neurons during the preceding REM sleep suppresses subsequent REM sleep and cataplexy. Thus, these results identify how...

  • Saved

2yr
Lemborexant and Daridorexant for the Treatment of Insomnia: an Indirect Comparison Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Lemborexant and Daridorexant for the Treatment of Insomnia: an Indirect Comparison Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Source : https://www.psychiatrist.com/jcp/sleep/lemborexant-daridorexant-treatment-insomnia-indirect-comparison-using-nnt-nnh-lhh/

This study examined whether differences existed between lemborexant and daridorexant in number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH) in...

In phase 3 trials, the benefit-risk ratios for both lemborexant and daridorexant were favorable as measured by NNT, NNH, and LHH. Indirect comparisons of lemborexant with daridorexant suggest an efficacy advantage for lemborexant and a tolerability advantage for daridorexant.

  • Saved

2yr
Internet-Delivered Cognitive Behavioral Therapy for Adolescents With Insomnia: Feasibility and Preliminary Efficacy

Internet-Delivered Cognitive Behavioral Therapy for Adolescents With Insomnia: Feasibility and Preliminary Efficacy

Source : https://pubmed.ncbi.nlm.nih.gov/37699436/

The present study indicates that ICBT-I is well accepted by adolescents, that insomnia symptoms and sleep parameters can improve following the intervention, and that co-morbid symptoms of depression can be...

The present study indicates that ICBT-I is well accepted by adolescents, that insomnia symptoms and sleep parameters can improve following the intervention, and that co-morbid symptoms of depression can be reduced. Due to the limited sample size and the uncontrolled design, the suggested results need to be replicated in well-powered...

  • Saved

2yr
Protocol for a Randomised Controlled Trial Evaluating the Effect of a CBT-I Smartphone Application (Sleep Ninja®) on Insomnia Symptoms in Children

Protocol for a Randomised Controlled Trial Evaluating the Effect of a CBT-I Smartphone Application (Sleep Ninja®) on Insomnia Symptoms in Children

Source : https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05185-x

Background Sleep is necessary for healthy development and mental wellbeing. Despite this, many children do not get the recommended duration of sleep each night, and many experience sleep problems. Although...

This is the first clinical trial examining the effects of a CBT-I smartphone app in children experiencing sleep disturbance. Results will provide empirical evidence about the effects of Sleep Ninja on insomnia and other mental health outcomes.

  • Saved

2yr
Decreases in daytime sleepiness distinguish daridorexant

Daridorexant is a dual orexin receptor antagonist (DORA), which alleviates the struggle with insomnia. It has been evaluated in clinical trials during a period of 12 months of nightly treatment. Experts believe that it targets an underlying biological cause of insomnia and blocks overactive wake signals rather than sedating the brain.

The half-life of daridorexant is 8 hours and is taken PO qn within 30 minutes of bedtime. In clinical trials, patients—including those aged 65 years or more—experienced clinical improvements during week 1 that continued over 3-4 weeks.

Daridorexant leverages the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ), a patient-reported outcome tool developed and validated according to FDA guidelines to evaluate daytime symptoms in patients with insomnia. During clinical trials, daridorexant 50 mg provided a statistically significant reduction in patient-reported daytime sleepiness, a secondary endpoint. Patients reported no evidence of physical dependence/withdrawal symptoms on discontinuation, with adverse reaction rates comparable between doses and vs. placebo.

For your patients with insomnia, how does the risk/benefit profile of 50 mg daridorexant qn compare with other DORAs you’ve prescribed? Which of these data points—efficacy, safety, or half-life—is most meaningful to you in choosing a DORA for your patients with insomnia?

  • 2yr
    Safe medications for the treatment of insomnia are very necessary especially in the older population that has the risk of falling, dependence, drug to drug interactions. But coverage of this Show More
  • 2yr
    Excited about this class of medication. This one in particular has no dosing adjustment for patients with renal impairment which is a bonus for diabetics and elderly individuals. Show More

Show More Comments